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eply
he CORONA (Controlled Rosuvastatin Multinational Trial in
eart Failure) study included a prespecified subgroup analysis
omparing outcomes in the two-thirds of patients at lower risk
ersus the one-third at higher risk (1). This showed a trend toward
reater benefit in patients with lower plasma N-terminal pro–B-
ype natriuretic peptide (NT-proBNP). Further analysis showed
hat this was driven by a substantial reduction in events in patients
ssigned to rosuvastatin in the lowest third of NT-proBNP (2).
here was no inconsistency between the analyses, as implied by
thyros et al.
The effect of statins in patients with milder heart failure may be
class effect. The subgroup analysis of the Treat to New Targets
tudy (3) suggesting benefit with atorvastatin should be interpreted
ith care because 47% of these 781 patients did not even require
iuretic treatment. The Treat to New Targets study provides no
vidence to support treating moderate or severe heart failure with
tatins. However, the lack of an adverse effect on outcome and the
eduction in hospitalization, even in patients in the highest third of
T-proBNP in the CORONA study provide no compelling
eason to withdraw statins as heart failure progresses other than to
educe polypharmacy. Rosuvastatin may be similarly effective in
educing the progression of vascular disease regardless of heart
ailure severity, but progression by other mechanisms may be the
ain driver of prognosis in patients with more severe heart failure.
We agree with the view of Drs. Barrios and Escobar and Dr.
thyros and colleagues that it is better to start statins in patients
ith or at substantial risk of the development of atheroma, long
efore the development of severe disease such as heart failure or
nd-stage kidney disease, another condition for which both ator-
astatin and rosuvastatin failed to provide clinical benefit (4). Some
atients are probably too well to benefit from statins and others too
ick. The largest treatment effect is likely to be in the mid-range of
isease severity in any target group (5). However, for the most part,
reatment of cardiovascular risk should be considered useful
rocrastination rather than prevention. Prevention implies that a
roblem has been solved and is no longer of concern. The onset of
eart failure may be delayed by modern treatment, but its overall
ncidence or prevalence does not seem to be decreasing; indeed,
odern therapy may be fueling the epidemic. Finding better ways
o manage heart failure should remain a high priority for the
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T-Segment Resolution and
utcome in Myocardial Infarction
ejersten et al. (1) explore the relationship between ST-segment
ecovery and outcome among patients enrolled in the DANAMI
DANish trial in Acute Myocardial Infarction)-2 study (1). In
eneral, their report joins a chorus of others establishing the
alidity of ST-segment recovery as a correlate of myocardial
eperfusion and predictor of outcomes among early ST-segment
levation myocardial infarction survivors. A key finding empha-
ized as “provocative,” however, was the absence of a relationship
inking ST-segment recovery to 30-day mortality among the
ubset of 602 patients assigned to primary percutaneous coronary
ntervention (PCI) in contrast to their fibrinolytic-treated patients.
Before accepting their call for further study, we suggest that
hey first reflect on previous work. A 2004 report of 700 patients
nrolled in the CADILLAC (Controlled Abciximab and Device
nvestigation to Lower Late Angioplasty Complications) trial
evealed a significant relationship between ST-segment recovery
n electrocardiograms acquired within 4 h of PCI (average 1.77 h)
nd both 30-day and 1-year mortality (2). We reported the relation-
hip between early ST-segment recovery (mean 32 min post-primary
CI) and 90-day mortality in 4,866 primary PCI patients enrolled in
he APEX-AMI (Assessment of the PEXilizumab in Acute Myo-
ardial Infarction) trial (3). Six previously published methods for
escribing ST-segment recovery were tested, including ST ele-
ation recovery; all provided robust prognostic information that
ersisted after adjustment for baseline variables and exclusion of
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April 13, 2010:1643–7hose with unsuccessful PCI or suboptimal post-PCI epicardial
ow (Thrombolysis In Myocardial Infarction flow grade 3).
Why the apparent discord? Our larger cohort provided more
nd-point events (144 vs. 27 deaths at 30 days). Moreover,
ejersten et al. (1) found a relationship between ST-segment
ecovery and mortality when both reperfusion strategies were
ggregated; hence, we believe that this is the key finding to
mphasize rather than diverse associations within each strategy
the interaction between ST-segment resolution, death, and treat-
ent assignment in their study was not significant [p  0.40]).
A substantial portion of ST-segment elevation myocardial
nfarction patients have suboptimal outcomes despite primary PCI.
n our study using a simple worst-lead residual ST-segment
levation method, we found that 32% of such patients had excess
ortality and morbidity.
The universally available, inexpensive, noninvasive ST-segment
ecovery metric provides a powerful tool for early prognostication.
his remains true regardless of the reperfusion strategy and can be
eadily incorporated into routine clinical practice and guidelines.
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eply
r. Buller and colleagues in a comment to our previously pub-
ished paper (1) call for some more reflection based on their
revious work in this field. ST-segment resolution turned out to be
uch a powerful prognosticater after fibrinolysis and became so
ecognized that it constitutes a paradigm. ST-segment resolutionas even been used as surrogate end point in several subsequent
rials. Our substudy from the DANAMI 2 trial (1) provided a
nique opportunity to explore the prognostic value of ST-segment
ecovery within the context of a randomized clinical trial compar-
ng fibrinolysis and primary percutaneous coronary intervention
PCI). Admittedly to our surprise, ST-segment recovery did not
redict 30-day mortality in the subset of 602 patients assigned to
rimary PCI. Dr. Buller and colleagues point to some of the
mportant differences between our study and their larger cohort
rom the APEX-AMI (Assessment of PEXilizumab in Acute
yocardial Infarction) trial (2) in which all patients were treated
ith primary PCI. It is possible that the earlier measure of
T-segment recovery after primary PCI (mean 32 min) provides a
tronger signal. We have subsequently calculated the earliest
vailable electrocardiogram in DANAMI-2 to be performed at
ean of 101 min post-PCI. Also, as pointed out in their larger
tudy, more end points occurred but still did not include a
omparably sized group treated with fibrinolysis for comparison.
The apparent discord with previous reports could also be
ublication bias. We are confident that there will be more
ublications in this field in the near future with further insight into
he background of our findings. Until then, ST-segment recovery
rovides a powerful tool for early recognition of failed reperfusion
fter fibrinolysis and thus prognostication. Furthermore, in this
ontext, the lack of ST-segment recovery has real clinical relevance
ecause rescue angioplasty can be offered, whereas the lack of
T-segment recovery after optimal primary PCI in the otherwise
ptimally medically managed patient is of little clinical conse-
uence.
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